JP2013063968A5 - - Google Patents

Download PDF

Info

Publication number
JP2013063968A5
JP2013063968A5 JP2012190429A JP2012190429A JP2013063968A5 JP 2013063968 A5 JP2013063968 A5 JP 2013063968A5 JP 2012190429 A JP2012190429 A JP 2012190429A JP 2012190429 A JP2012190429 A JP 2012190429A JP 2013063968 A5 JP2013063968 A5 JP 2013063968A5
Authority
JP
Japan
Prior art keywords
group
alkyl group
alkoxy
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012190429A
Other languages
English (en)
Japanese (ja)
Other versions
JP6091811B2 (ja
JP2013063968A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012190429A priority Critical patent/JP6091811B2/ja
Priority claimed from JP2012190429A external-priority patent/JP6091811B2/ja
Publication of JP2013063968A publication Critical patent/JP2013063968A/ja
Publication of JP2013063968A5 publication Critical patent/JP2013063968A5/ja
Application granted granted Critical
Publication of JP6091811B2 publication Critical patent/JP6091811B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012190429A 2011-08-31 2012-08-30 ピラゾール化合物及びその医薬用途 Active JP6091811B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012190429A JP6091811B2 (ja) 2011-08-31 2012-08-30 ピラゾール化合物及びその医薬用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011188121 2011-08-31
JP2011188121 2011-08-31
JP2012190429A JP6091811B2 (ja) 2011-08-31 2012-08-30 ピラゾール化合物及びその医薬用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017021326A Division JP2017082005A (ja) 2011-08-31 2017-02-08 ピラゾール化合物及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2013063968A JP2013063968A (ja) 2013-04-11
JP2013063968A5 true JP2013063968A5 (cg-RX-API-DMAC10.html) 2015-10-15
JP6091811B2 JP6091811B2 (ja) 2017-03-08

Family

ID=47756400

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012190429A Active JP6091811B2 (ja) 2011-08-31 2012-08-30 ピラゾール化合物及びその医薬用途
JP2017021326A Ceased JP2017082005A (ja) 2011-08-31 2017-02-08 ピラゾール化合物及びその医薬用途
JP2018088578A Ceased JP2018115216A (ja) 2011-08-31 2018-05-02 ピラゾール化合物及びその医薬用途
JP2020081097A Ceased JP2020125348A (ja) 2011-08-31 2020-05-01 ピラゾール化合物及びその医薬用途
JP2023075967A Ceased JP2023087032A (ja) 2011-08-31 2023-05-02 ピラゾール化合物及びその医薬用途
JP2025000092A Withdrawn JP2025039641A (ja) 2011-08-31 2025-01-06 ピラゾール化合物及びその医薬用途

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017021326A Ceased JP2017082005A (ja) 2011-08-31 2017-02-08 ピラゾール化合物及びその医薬用途
JP2018088578A Ceased JP2018115216A (ja) 2011-08-31 2018-05-02 ピラゾール化合物及びその医薬用途
JP2020081097A Ceased JP2020125348A (ja) 2011-08-31 2020-05-01 ピラゾール化合物及びその医薬用途
JP2023075967A Ceased JP2023087032A (ja) 2011-08-31 2023-05-02 ピラゾール化合物及びその医薬用途
JP2025000092A Withdrawn JP2025039641A (ja) 2011-08-31 2025-01-06 ピラゾール化合物及びその医薬用途

Country Status (28)

Country Link
US (5) US8846746B2 (cg-RX-API-DMAC10.html)
EP (4) EP3199533B1 (cg-RX-API-DMAC10.html)
JP (6) JP6091811B2 (cg-RX-API-DMAC10.html)
KR (1) KR101989203B1 (cg-RX-API-DMAC10.html)
CN (1) CN103917535B (cg-RX-API-DMAC10.html)
AR (2) AR087701A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012302723B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014004651B1 (cg-RX-API-DMAC10.html)
CA (1) CA2845127C (cg-RX-API-DMAC10.html)
CL (1) CL2014000490A1 (cg-RX-API-DMAC10.html)
CO (1) CO6890098A2 (cg-RX-API-DMAC10.html)
CY (1) CY1121631T1 (cg-RX-API-DMAC10.html)
DK (1) DK3199533T3 (cg-RX-API-DMAC10.html)
HK (1) HK1202290A1 (cg-RX-API-DMAC10.html)
IL (1) IL230763A (cg-RX-API-DMAC10.html)
MX (1) MX359825B (cg-RX-API-DMAC10.html)
MY (1) MY172422A (cg-RX-API-DMAC10.html)
PE (1) PE20142343A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014500444A1 (cg-RX-API-DMAC10.html)
PL (1) PL3199533T3 (cg-RX-API-DMAC10.html)
RS (1) RS58870B1 (cg-RX-API-DMAC10.html)
RU (1) RU2617678C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201400244YA (cg-RX-API-DMAC10.html)
SI (1) SI3199533T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201900292T1 (cg-RX-API-DMAC10.html)
TW (1) TWI549949B (cg-RX-API-DMAC10.html)
WO (1) WO2013031922A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201401071B (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
WO2013168671A1 (ja) 2012-05-07 2013-11-14 キッセイ薬品工業株式会社 ピラゾール誘導体及びその医薬用途
WO2014076162A1 (en) 2012-11-19 2014-05-22 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines
AU2014213251B2 (en) * 2013-02-04 2017-07-20 Taisho Pharmaceutical Co., Ltd. Prophylactic or therapeutic drug for constipation
EP2994155B1 (en) 2013-05-08 2020-12-23 The University of Houston System Targeting the egfr-sglt1 interaction for cancer therapy
CN105294703B (zh) * 2015-10-23 2018-01-23 西安近代化学研究所 3,7,10‑三氧代‑2,4,6,8,9,11‑六氮杂[3,3,3]螺桨烷的合成方法
JP2019526547A (ja) 2016-08-11 2019-09-19 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 置換されているピラゾリニル誘導体、それらを製造する方法、並びに、除草剤及び/又は植物成長調節剤としてのそれらの使用
CN109563048B (zh) 2016-08-15 2022-05-06 拜耳农作物科学股份公司 用于制备3-氨基-1-(2,6-二取代的苯基)吡唑的方法
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
CA3089092A1 (en) * 2018-04-04 2019-10-10 Japan Tobacco Inc. Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
EP4026564A4 (en) * 2019-09-04 2023-03-15 Japan Tobacco Inc. THERAPEUTIC OR PROPHYLACTIC PROCEDURE FOR DIABETES USING COMBINATION MEDICATION
CN114641314B (zh) * 2019-09-04 2024-05-28 日本烟草产业株式会社 慢性肾脏病的治疗或预防方法
BR112022018396A2 (pt) 2020-03-19 2022-11-08 Japan Tobacco Inc Método de tratamento ou prevenção para insuficiência cardíaca crônica

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
PL353455A1 (en) * 1999-08-12 2003-11-17 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
DE60332743D1 (de) * 2002-08-08 2010-07-08 Kissei Pharmaceutical Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
MX2007005137A (es) 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
EP1951678A1 (en) 2005-10-21 2008-08-06 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
JP5069894B2 (ja) 2005-10-21 2012-11-07 田辺三菱製薬株式会社 ピラゾール化合物
US20070117858A1 (en) 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
WO2008045484A1 (en) * 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
JP4994295B2 (ja) 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP2010222298A (ja) * 2009-03-24 2010-10-07 Shionogi & Co Ltd Npyy5受容体拮抗作用を有するピロリドン誘導体
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
CN102985405B (zh) 2010-07-02 2016-07-06 Aska制药株式会社 杂环化合物及p27Kip1分解抑制剂
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1

Similar Documents

Publication Publication Date Title
JP2013063968A5 (cg-RX-API-DMAC10.html)
SA522432955B1 (ar) Kras g12c مثبطات
EA201391629A1 (ru) Ингибиторы цсж-1r для лечения опухолей головного мозга
JP2013531029A5 (cg-RX-API-DMAC10.html)
MD4666B1 (ro) Inhibitori ai Syk
EA201590020A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
MX2018010878A (es) Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
RU2014112048A (ru) Пиразольное соединение и его применение в фармацевтике
EA201590023A1 (ru) Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
EA201690094A1 (ru) Ингибиторы syk
MX2012008221A (es) Inhibidores de virus flaviviridae.
JP2011513305A5 (cg-RX-API-DMAC10.html)
MX2012008211A (es) Inhibidores de virus flaviviridae.
EA201490407A1 (ru) Содержащие гидразид модуляторы нуклеарного транспорта и их применения
UA115320C2 (uk) Інгібітори кінази
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
JP2015504081A5 (cg-RX-API-DMAC10.html)
WO2014128669A3 (en) Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
EA201391558A1 (ru) Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
EA201590021A1 (ru) Новые замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
JP2016537382A5 (cg-RX-API-DMAC10.html)
IN2014DN07283A (cg-RX-API-DMAC10.html)